XNAS · RARE
+0.00% · +$0.0000 · Vol Not reported
Market closed · last close shown
Ultragenyx Pharmaceutical Inc.

Ultragenyx Pharmaceutical Inc.

PHARMACEUTICAL PREPARATIONS
$33.47

Veridion Score

Refresh
Score snapshot refresh in progress
Veridion Score History · 90D

Composite trend over time

HISTORY REFRESH IN PROGRESS
REFRESHES DAILY
AI Analysis
Sovereign

Why is RARE moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.
About Ultragenyx Pharmaceutical Inc.
PHARMACEUTICAL PREPARATIONS
Listed since
2014
Employees
1K
Country
US

Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. The company identifies, acquires, develops, and commercializes novel products for the treatment of serious, rare, and ultra-rare diseases, with a focus on debilitating genetic conditions. Its medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients aged one year and older. Mepsevii is indicated for pediatric and adult patients for the treatment of Mucopolysaccharidosis VII. The company operates across North America, Latin America, Europe, the Middle East and Africa, and Asia-Pacific, with the majority of its revenue generated from North America.

Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$33.47
Last session
Day high
$33.47
Last session
Day low
$33.47
Last session
Previous close
$33.47
52W high
$33.47
0.00% from high
52W low
$33.47
Market cap
$3.3B
EPS
$-6.3900
Shares out
98.5M
VWAP
$33.47
Last session
Veridion warehouse edge

Warehouse intelligence for RARE.

Disclosure-sourced lobbying and contract detail remains attributed in the full panels below.
Data ledger
Quote and day range
Refresh interval: 30 seconds
Source: Market data
Veridion Score
Coverage building
Chart and risk context
Daily bars with no missing-bar fill
Source: Market data
News and filings
Refresh intervals shown inside each panel
Source: Market news and federal filings
Financials
Statements refresh in progress
SEC Form 4 ledger

RARE insider activity

Ultragenyx Pharmaceutical Inc.

Score
Coverage building
Pressure
Net selling
Filings
28
Buys / sells
0 / 28
Net value
-$3.7M
Insiders
10
Named filers
SD
Sanders Corazon (Corsee) D.
Insider
Leadership
PH
Parschauer Karah Herdman
Insider
Leadership
HH
Horn Howard
Insider
Leadership
Cluster

No multi-insider buying cluster in the last 90 days

Net pressure

Net selling: -$3.7M across loaded Form 4 rows.

Convergence not established

Loaded official disclosures do not show all three sources aligned on this ticker.

Filing dateTrade dateInsiderTitleTypePriceQtyOwnedValueReceipt
2026-06-152026-06-15Sanders Corazon (Corsee) D.Insidersell$25.052,00021,095$50KSEC Form 4
2026-06-152026-06-15Parschauer Karah HerdmanInsidersell$24.621,89994,462$47KSEC Form 4
2026-06-012026-06-01Horn HowardInsidersell$23.774,653105,689$111KSEC Form 4
2026-05-182026-05-18SULIMAN SHEHNAAZInsidersell$25.125,74027,951$144KSEC Form 4
2026-05-062026-05-05Crombez EricInsidersell$24.96344111,189$9KSEC Form 4
Full Form 4 history requires Sovereign

Showing 5 recent rows. Sovereign unlocks 23 additional rows, full sorting, and the named-filer history.

Upgrade to Sovereign · $25/mo
Source: SEC EDGAR Form 4. Rows with missing price or quantity are excluded rather than zero-filled.Methodology
Congress · 90D
Congress filing snapshot refresh in progress
Federal contracts

RARE contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for RARE in this window.
Lobbying spend

RARE lobbying filings, year to date.

Registered lobbying filings matched to Ultragenyx Pharmaceutical Inc..

Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for RARE in this window.
Latest news · RARE
Refresh interval: 5 minutes · Source: Market news insights
News snapshot refresh in progress
Analyst ratings
Sovereign unlock shows live analyst consensus for RARE.
Options
Sovereign unlock shows live options positioning for RARE.
Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.